MXPA02007632A - Derivados de 2-benzotiazolil urea y su uso como inhibidores de proteina cinasa. - Google Patents

Derivados de 2-benzotiazolil urea y su uso como inhibidores de proteina cinasa.

Info

Publication number
MXPA02007632A
MXPA02007632A MXPA02007632A MXPA02007632A MXPA02007632A MX PA02007632 A MXPA02007632 A MX PA02007632A MX PA02007632 A MXPA02007632 A MX PA02007632A MX PA02007632 A MXPA02007632 A MX PA02007632A MX PA02007632 A MXPA02007632 A MX PA02007632A
Authority
MX
Mexico
Prior art keywords
protein kinase
kinase inhibitors
urea derivatives
inhibitors
benzothiazolyl urea
Prior art date
Application number
MXPA02007632A
Other languages
English (en)
Inventor
Anna Ericsson
Original Assignee
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg
Publication of MXPA02007632A publication Critical patent/MXPA02007632A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Abstract

La presente invencion es dirigida a un compuesto de formula (l), mezclas racemicas-diastereomericas del mismo, isomeros opticos del mismo, promedicamentos del mismo, isotopos del mismo o sales farmaceuticamente aceptables de dicho compuesto, isomeros, promedicamentos e isotopos, en donde las variables son definidas en la presente. Los compuestos de esta invencion son utiles como inhibidores de serina/treonina y tirosina cinasas. En particular, compuestos de esta invencion son utiles como inhibidores de tirosina cinasas, que son importantes en enfermedades hiper-proliferativas, especialmente en cancer y en el proceso de angiogenesis. (ver formula).
MXPA02007632A 2000-02-07 2001-02-06 Derivados de 2-benzotiazolil urea y su uso como inhibidores de proteina cinasa. MXPA02007632A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18084100P 2000-02-07 2000-02-07
PCT/US2001/003803 WO2001057008A1 (en) 2000-02-07 2001-02-06 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors

Publications (1)

Publication Number Publication Date
MXPA02007632A true MXPA02007632A (es) 2004-08-23

Family

ID=22661941

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02007632A MXPA02007632A (es) 2000-02-07 2001-02-06 Derivados de 2-benzotiazolil urea y su uso como inhibidores de proteina cinasa.

Country Status (18)

Country Link
US (1) US7091227B2 (es)
EP (1) EP1254123A1 (es)
JP (1) JP2003521543A (es)
KR (1) KR20020084116A (es)
CN (1) CN1422262A (es)
AR (1) AR030189A1 (es)
AU (1) AU2001236698A1 (es)
BG (1) BG107062A (es)
BR (1) BR0108085A (es)
CA (1) CA2398754A1 (es)
HU (1) HUP0300359A2 (es)
IL (1) IL151045A0 (es)
MX (1) MXPA02007632A (es)
NO (1) NO20023713L (es)
PL (1) PL357099A1 (es)
SK (1) SK12712002A3 (es)
WO (1) WO2001057008A1 (es)
ZA (1) ZA200206235B (es)

Families Citing this family (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP1158985B1 (en) 1999-01-13 2011-12-28 Bayer HealthCare LLC OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
EP1303483B1 (en) * 2000-08-21 2008-04-23 Pacific Corporation Novel thiourea derivatives and the pharmaceutical compositions containing the same
US6492521B2 (en) * 2000-11-03 2002-12-10 Cytec Technology Corp. Hindered amine light stabilizers based on multi-functional carbonyl compounds and methods of making same
US6727247B2 (en) 2001-12-10 2004-04-27 Hoffman-La Roche Inc. Substituted benzothiazole amide derivatives
PT1478358E (pt) 2002-02-11 2013-09-11 Bayer Healthcare Llc Tosilato de sorafenib para o tratamento de doenças caracterizadas por angiogénese anormal
WO2003068229A1 (en) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
KR101116627B1 (ko) 2002-06-27 2012-10-09 노보 노르디스크 에이/에스 치료제로서 아릴 카르보닐 유도체
KR101124245B1 (ko) 2002-06-27 2012-07-02 노보 노르디스크 에이/에스 치료제로서 아릴 카르보닐 유도체
WO2004014922A1 (en) * 2002-08-10 2004-02-19 Astex Technology Limited 3-(carbonyl) 1h-indazole compounds as cyclin dependent kinases (cdk) inhibitors
US20040034038A1 (en) * 2002-08-13 2004-02-19 Goaquan Li Urea kinase inhibitors
US7056925B2 (en) 2002-08-13 2006-06-06 Abbott Laboratories Urea kinase inhibitors
EP2426122A1 (en) * 2002-10-24 2012-03-07 Merck Patent GmbH Methylene urea derivative as RAF kinasse inhibitors
PL374758A1 (en) * 2002-10-24 2005-10-31 Merck Patent Gmbh Methylene urea derivatives
US7582635B2 (en) 2002-12-24 2009-09-01 Purdue Pharma, L.P. Therapeutic agents useful for treating pain
US7186725B2 (en) * 2003-01-03 2007-03-06 Genzyme Corporation Anti-inflammatory compositions and methods
US7390670B2 (en) * 2003-02-20 2008-06-24 Lumigen, Inc. Signalling compounds and methods for detecting hydrogen peroxide
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
EP1599466B1 (en) * 2003-02-28 2010-11-24 Bayer HealthCare LLC 2-oxo-1,3,5-perhydrotriazapine derivatives useful in the treatment of hyper-proliferative, angiogenesis, and inflammatrory disorders
ATE440835T1 (de) * 2003-03-06 2009-09-15 Glaxo Group Ltd Heterozyklische harnstoff-derivate für die behandlung von schmerzen.
US7514562B2 (en) * 2003-03-07 2009-04-07 Glaxo Group Limited Urea derivatives and their use as vanilloid receptor antagonists in the treatment of pain
GB0305426D0 (en) * 2003-03-08 2003-04-16 Glaxo Group Ltd Novel compounds
DE602004011340T2 (de) 2003-05-20 2008-11-06 Bayer Healthcare Llc Diaryl-harnstoffe mit kinasehemmender wirkung
AR045037A1 (es) 2003-07-10 2005-10-12 Aventis Pharma Sa Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion.
UA84156C2 (ru) 2003-07-23 2008-09-25 Байер Фармасьютикалс Корпорейшн Фторозамещённая омега-карбоксиарилдифенилмочевина для лечения и профилактики болезней и состояний
EP2392564B1 (en) * 2003-09-26 2013-10-23 Exelixis, Inc. c-Met modulators and methods of use
WO2005037845A1 (en) * 2003-10-17 2005-04-28 Rigel Pharmaceuticals, Inc. Benzothiazole and thiazole[5,5-b] pyridine compositions and their use as ubiquitin ligase inhibitors
US20050197371A1 (en) 2003-11-13 2005-09-08 Ambit Biosciences Corporation Urea derivatives as PDGFR modulators
JP4834840B2 (ja) 2004-01-06 2011-12-14 ノヴォ ノルディスク アー／エス ヘテロアリール尿素およびグルコキナーゼ活性化剤としてのその使用
EP1711495A2 (en) * 2004-01-23 2006-10-18 Amgen Inc. Quinoline, quinazoline, pyridine and pyrimidine counds and their use in the treatment of inflammation, angiogenesis and cancer
FR2868421B1 (fr) * 2004-04-01 2008-08-01 Aventis Pharma Sa Nouveaux benzothiazoles et leur utilisation comme medicaments
US7550499B2 (en) * 2004-05-12 2009-06-23 Bristol-Myers Squibb Company Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
EP1778658A2 (en) * 2004-07-20 2007-05-02 Siena Biotech S.p.A. Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof
WO2006040279A1 (de) * 2004-10-07 2006-04-20 Boehringer Ingelheim International Gmbh Pi3-kinasen
EP1799669A1 (en) 2004-10-13 2007-06-27 Merck Patent GmbH Heterocyclic substituted bisarylurea derivatives as kinase inhibitors
PT1828177E (pt) 2004-12-17 2008-10-28 Lilly Co Eli Novos antagonistas dos receptores da mch
DE112005003227T5 (de) * 2004-12-30 2007-11-15 Chemagis Ltd. Neues Verfahren zur Herstellung von Pramipexol und dem Gemisch seiner optischen Isomeren durch Reduktion mit Natriumtriacetoxyborhydrid
KR20060079098A (ko) * 2004-12-31 2006-07-05 주식회사 엘지생명과학 신규한([1,3]티아졸로[5,4-ｂ]피리딘-2-일)-2-카르복사마이드유도체
DE602006020327D1 (de) * 2005-01-19 2011-04-07 Bristol Myers Squibb Co 2-phenoxy-n-(1,3,4-thiadizol-2-yl)pyridin-3-aminder-hemmer zur behandlung thromboembolischer erkrankungen
TW200640443A (en) * 2005-02-23 2006-12-01 Alcon Inc Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
GB0508471D0 (en) * 2005-04-26 2005-06-01 Celltech R&D Ltd Therapeutic agents
ATE485269T1 (de) * 2005-06-27 2010-11-15 Bristol Myers Squibb Co C-verknüpfte zyklische antagonisten des p2y1- rezeptors mit eignung bei der behandlung thrombotischer leiden
US7816382B2 (en) 2005-06-27 2010-10-19 Bristol-Myers Squibb Company Linear urea mimics antagonists of P2Y1 receptor useful in the treatment of thrombotic condition
WO2007002637A1 (en) 2005-06-27 2007-01-04 Bristol-Myers Squibb Company N-linked heterocyclic antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
US7714002B2 (en) 2005-06-27 2010-05-11 Bristol-Myers Squibb Company Carbocycle and heterocycle antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
EP1928848A2 (en) * 2005-08-04 2008-06-11 Apogee Biothechnology Corporation Sphingosine kinase inhibitors and methods of their use
FR2891273B1 (fr) * 2005-09-27 2007-11-23 Aventis Pharma Sa NOUVEAUX DERIVES BENZIMIDAZOLES ET BENZOTHIAZOLES, LEUR PREPARATION ET LEUR UTILISATION PHARMACEUTIQUE NOTAMMENT COMME INHIBITEURS DE CMet
PE20070978A1 (es) * 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
GB0606429D0 (en) * 2006-03-30 2006-05-10 Novartis Ag Organic compounds
US20070259855A1 (en) * 2006-04-06 2007-11-08 Udo Maier Thiazolyl-dihydro-indazole
US20070238718A1 (en) * 2006-04-06 2007-10-11 Matthias Grauert Thiazolyl-dihydro-indazole
US7691868B2 (en) * 2006-04-06 2010-04-06 Boehringer Ingelheim International Gmbh Thiazolyl-dihydro-quinazoline
EP2007773B1 (de) 2006-04-06 2012-10-24 Boehringer Ingelheim International GmbH Thiazolyl-dihydro-indazole
CA2647278A1 (en) 2006-04-06 2007-10-11 Boehringer Ingelheim International Gmbh Thiazolyldihydroindazole derivatives as protein kinase inhibitors
US7517995B2 (en) 2006-04-06 2009-04-14 Boehringer Ingelheim International Gmbh Thiazolyl-dihydro-cyclopentapyrazole
US20070238746A1 (en) 2006-04-06 2007-10-11 Trixi Brandl Thiazolyl-dihydro-chinazoline
JP5334844B2 (ja) * 2006-06-14 2013-11-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規化合物
GB0612428D0 (en) 2006-06-22 2006-08-02 Prolysis Ltd Antibacterial agents
US8481544B2 (en) 2006-06-22 2013-07-09 Biota Europe Limited Antibacterial compositions
DE602006002385D1 (de) * 2006-06-26 2008-10-02 Helm Ag Verfahren zur Herstellung von Pramipexole
JP5258563B2 (ja) * 2006-06-29 2013-08-07 日産化学工業株式会社 αアミノ酸誘導体及びそれを有効成分として含む医薬
US7960569B2 (en) 2006-10-17 2011-06-14 Bristol-Myers Squibb Company Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
CL2008000119A1 (es) * 2007-01-16 2008-05-16 Wyeth Corp Compuestos derivados de pirazol, antagonistas del receptor nicotinico de acetilcolina; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como demencia senil, alzheimer y esquizofrenia.
ES2453947T3 (es) * 2007-04-27 2014-04-09 Purdue Pharma Lp Antagonistas de TRPV1 y usos de los mismos
AU2008246202B2 (en) 2007-04-27 2011-12-01 Purdue Pharma L.P. Therapeutic agents useful for treating pain
CL2008001626A1 (es) * 2007-06-05 2009-06-05 Takeda Pharmaceuticals Co Compuestos derivados de heterociclos fusionados, agente farmaceutico que los comprende y su uso en la profilaxis y tratamiento del cancer.
WO2009010530A1 (en) * 2007-07-18 2009-01-22 Novartis Ag Bicyclic heteroaryl compounds and their use as kinase inhibitors
EP2183232B1 (en) * 2007-08-02 2013-03-06 Amgen, Inc Pi3 kinase modulators and methods of use
US8324395B2 (en) 2007-08-23 2012-12-04 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
FR2922550B1 (fr) 2007-10-19 2009-11-27 Sanofi Aventis Nouveaux derives de 6-aryl/heteroalkyloxy benzothiazole et benzimidazole, application comme medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de cmet
GB0724342D0 (en) * 2007-12-13 2008-01-30 Prolysis Ltd Anitbacterial compositions
CA2710194C (en) * 2007-12-19 2014-04-22 Amgen Inc. Inhibitors of p13 kinase
WO2009111644A2 (en) * 2008-03-05 2009-09-11 The Regents Of The University Of Michigan Compositions and methods for diagnosing and treating pancreatic cancer
WO2009133127A1 (en) * 2008-04-30 2009-11-05 Merck Serono S.A. Fused bicyclic compounds and use thereof as pi3k inhibitors
US20110142839A1 (en) * 2008-05-30 2011-06-16 Vegenics Limited Treatment of pulmonary edema
JP2011525535A (ja) * 2008-06-24 2011-09-22 武田薬品工業株式会社 ＰＩ３Ｋ／ｍＴＯＲ阻害剤
US20110257171A1 (en) * 2008-07-18 2011-10-20 Sanofi-Aventis Novel imidazo[1,2-a]pyridine derivatives, method for the preparation thereof, use thereof as medicaments, pharmaceutical compositions and novel use in particular as met inhibitors
FR2933981A1 (fr) * 2008-07-18 2010-01-22 Sanofi Aventis NOUVEAUX DERIVES IMIDAZO°1,2-a!PYRIDINE, LEUR PROCEDE DE PREPARATION, LEUR APPLICATION A TITRE DE MEDICAMENTS, COMPOSITIONS PHARMACEUTIQUES ET NOUVELLE UTILISATION NOTAMMENT COMME INHIBITEURS DE MET
FR2933980B1 (fr) * 2008-07-18 2011-07-29 Sanofi Aventis Nouveaux derives triazolo°4,3-a!pyridine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met
FR2945806B1 (fr) * 2009-05-19 2013-04-05 Sanofi Aventis Nouveaux derives imidazo[1,2-a]pyridine,procede de preparation,medicaments,compositions pharmaceutiques et utilisation notamment comme inhibiteurs de met
FR2933982A1 (fr) * 2008-07-18 2010-01-22 Sanofi Aventis Nouveaux derives imidazo°1,2-a!pyrimidine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met
US8759362B2 (en) * 2008-10-24 2014-06-24 Purdue Pharma L.P. Bicycloheteroaryl compounds and their use as TRPV1 ligands
US8703962B2 (en) * 2008-10-24 2014-04-22 Purdue Pharma L.P. Monocyclic compounds and their use as TRPV1 ligands
JP5579619B2 (ja) 2008-12-01 2014-08-27 武田薬品工業株式会社 複素環化合物およびその用途
JO3101B1 (ar) 2008-12-02 2017-09-20 Takeda Pharmaceuticals Co مشتقات بنزوثيازول كعوامل مضادة للسرطان
BRPI0918337A2 (pt) * 2008-12-19 2017-05-30 Abbott Lab composto, composição farmacêutica, método de tratamento, método para tratar uma doença ou condição causada, exacerbada ou resultante de um excesso de plaquetas ou ativação indesejada de plaquetas em um paciente, método para reduzir a contagem de plaquetas circulantes em um paciente e uso
KR20240011244A (ko) 2009-01-16 2024-01-25 엑셀리시스, 인코포레이티드 암의 치료를 위한 ｎ-（４-｛〔６，７-비스（메틸옥시）퀴놀린-4-일〕옥시｝페닐）-ｎ＇-（４-플루오로페닐）사이클로프로판-1,1-디카르복사미드의 말산염 및 그 결정형
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
JP6088425B2 (ja) * 2010-06-01 2017-03-01 アンジオン バイオメディカ コーポレーション チトクロームｐ４５０阻害剤およびその使用
WO2011162409A1 (en) 2010-06-22 2011-12-29 Shionogi & Co., Ltd. Compounds having trpv1 antagonistic activity and uses thereof
PE20141531A1 (es) 2011-06-22 2014-10-23 Purdue Pharma Lp Antagonistas de trpv1 que incluyen sustituyentes dihidroxi y sus usos
AU2012293417A1 (en) 2011-08-10 2013-05-02 Purdue Pharma L.P. TRPV1 antagonists including dihydroxy substituent and uses thereof
CN103857683B (zh) 2011-09-30 2016-10-12 奇尼塔公司 抗病毒化合物
CN103987711B (zh) 2011-10-14 2016-08-24 艾伯维公司 作为用于治疗癌症和免疫性和自身免疫性疾病的凋亡诱导剂的8-氨基甲酰基-2-(2,3-二取代吡啶-6-基)-1,2,3,4-四氢异喹啉衍生物
CN103958508B (zh) 2011-10-14 2019-02-12 艾伯维公司 用于治疗癌症以及免疫与自身免疫性疾病的细胞凋亡诱导剂
EP2766359B9 (en) * 2011-10-14 2017-04-05 Ambit Biosciences Corporation Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases
WO2013138753A1 (en) 2012-03-16 2013-09-19 Fox Chase Chemical Diversity Center, Inc. Prodrugs of riluzole and their method of use
MA37975B2 (fr) * 2012-09-11 2021-03-31 Genzyme Corp Inhibiteurs de synthase de glucosylcéramide
US9073946B2 (en) * 2013-01-15 2015-07-07 Kineta, Inc. Anti-viral compounds
ES2489297B1 (es) 2013-01-22 2015-06-10 Consejo Superior De Investigaciones Científicas (Csic) Benzotiazoles sustituidos y sus aplicaciones terapeuticas para el tratamiento de enfermedades humanas
GB201401886D0 (en) * 2014-02-04 2014-03-19 Lytix Biopharma As Neurodegenerative therapies
CN105175408B (zh) * 2014-06-04 2018-07-17 中国人民解放军第二军医大学 苯并噻唑类化合物及其作为药物的用途
CN104402875A (zh) * 2014-12-25 2015-03-11 西安山川医药科技有限公司 N-(2-氨基乙基)-n′-(6-取代-2-苯并噻唑基)脲及其盐类化合物的合成方法和用途
CN106810536A (zh) 2015-11-30 2017-06-09 甘李药业股份有限公司 一种蛋白激酶抑制剂及其制备方法和医药用途
CN107641118B (zh) * 2016-07-22 2020-11-06 爱科诺生物医药股份有限公司 具有细胞坏死抑制活性的化合物及其组合物和应用
KR101838615B1 (ko) 2016-09-30 2018-03-15 숙명여자대학교산학협력단 신규한 벤조옥사졸 또는 벤조티아졸 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
CN106632403B (zh) * 2017-01-23 2018-09-11 牡丹江医学院 一种手术用止痛消炎药及其制备方法
WO2018224455A1 (en) 2017-06-07 2018-12-13 Basf Se Substituted cyclopropyl derivatives
KR20200051832A (ko) 2017-10-02 2020-05-13 (주)퍼스트바이오 테라퓨틱스 벤조티아졸 화합물 및 신경퇴행성 질환을 치료하기 위한 그의 사용 방법
CA3084809A1 (en) * 2017-12-07 2019-06-13 The Regents Of The University Of Michigan Nsd family inhibitors and methods of treatment therewith
US11731985B2 (en) 2018-05-10 2023-08-22 Hb Therapeutics Inc. Compositions and methods for treating cancer
JP2021526130A (ja) 2018-06-12 2021-09-30 ブイティーブイ・セラピューティクス・エルエルシー インスリンまたはインスリン類似体と組み合わせたグルコキナーゼ活性化薬の治療的使用
CN108912115A (zh) * 2018-07-02 2018-11-30 秦继伟 一种用于治疗肺癌的egfr酪氨酸激酶抑制剂
CN108570044A (zh) * 2018-07-02 2018-09-25 秦继伟 一种酰胺类化合物及其合成方法和治疗癌症的用途
CN108690013A (zh) * 2018-07-02 2018-10-23 秦继伟 苯并[d]噻唑衍生物及其作为EGFR抑制剂在癌症治疗中的应用
CN108997309A (zh) * 2018-07-17 2018-12-14 中国科学技术大学苏州研究院 一种吡唑-4-芳基衍生物的制备方法
CN113271941A (zh) * 2018-10-17 2021-08-17 法国国家科学研究中心 用于治疗和/或预防癌症的脲衍生物
AU2020224401A1 (en) 2019-02-22 2021-10-14 1ST Biotherapeutics, Inc. Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders
KR20210122192A (ko) * 2020-03-30 2021-10-08 주식회사 이노큐어테라퓨틱스 벤조티아졸 유도체 화합물
AU2021311131A1 (en) 2020-07-24 2023-03-23 Genzyme Corporation Pharmaceutical compositions comprising venglustat
JPWO2022059779A1 (es) * 2020-09-18 2022-03-24
WO2022059778A1 (ja) * 2020-09-18 2022-03-24 カルナバイオサイエンス株式会社 環状ウレア誘導体
WO2023008472A1 (ja) * 2021-07-28 2023-02-02 カルナバイオサイエンス株式会社 新規ベンゾチアゾール誘導体

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH505543A (de) * 1968-11-01 1971-04-15 Ciba Geigy Ag Schädlingsbekämpfungsmittel
US3810988A (en) * 1968-11-01 1974-05-14 Ciba Geigy Ag Control of phytopathogenic fungi with n-benzothiazae-2-yl n-{40 {11 propylure
JPS53124265A (en) 1977-04-06 1978-10-30 Nippon Tokushu Noyaku Seizo Kk Urea or thiourea type compounds, their preparation and insecticides contaning the same as active agent
JPS57175189A (en) 1981-04-21 1982-10-28 Kyowa Hakko Kogyo Co Ltd Benzothiazole derivative and its preparation
US4966849A (en) * 1985-09-20 1990-10-30 President And Fellows Of Harvard College CDNA and genes for human angiogenin (angiogenesis factor) and methods of expression
JPS62187842A (ja) 1985-10-25 1987-08-17 Konishiroku Photo Ind Co Ltd ハロゲン化銀写真感光材料
US5217999A (en) * 1987-12-24 1993-06-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Styryl compounds which inhibit EGF receptor protein tyrosine kinase
ATE114661T1 (de) 1990-04-02 1994-12-15 Pfizer Benzylphosphonsäure-tyrosinkinaseinhibitoren.
US5302606A (en) * 1990-04-16 1994-04-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase
ATE159009T1 (de) 1991-05-10 1997-10-15 Rhone Poulenc Rorer Int Bis mono- und bicyclische aryl- und heteroarylderivate mit inhibierender wirkung auf die egf und/oder pdgf-rezeptor tyrosinkinase
JPH06503095A (ja) 1991-05-29 1994-04-07 ファイザー・インコーポレーテッド 三環式ポリヒドロキシ系のチロシンキナーゼ阻害薬
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
JPH08503450A (ja) 1992-08-06 1996-04-16 ワーナー−ランバート・コンパニー 蛋白チロシンキナーゼを阻害し、かつ抗腫瘍特性を有する２−チオインドール（セレノインドール）および関連ジスルフィド（セレニド）
US5330992A (en) * 1992-10-23 1994-07-19 Sterling Winthrop Inc. 1-cyclopropyl-4-pyridyl-quinolinones
EP1167384B1 (en) 1992-10-28 2006-12-13 Genentech, Inc. HVEGF Receptor as Vascular endothelial cell growth factor antagonists
GB9226855D0 (en) 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
DE69734149T2 (de) 1996-03-15 2006-07-06 Astrazeneca Ab Cinoline derivate und verwendung als heilmittel
EP0915698A4 (en) 1996-05-01 1999-08-11 Lilly Co Eli TREATMENT PROCEDURE FOR VEGF-RELATED DISEASES
UA54427C2 (uk) 1996-05-01 2003-03-17 Елі Ліллі Енд Компані Спосіб лікування очних захворювань, які пов'язані з фактором васкулярного ендотеліального росту
GB9707800D0 (en) 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
TW513418B (en) 1996-07-31 2002-12-11 Otsuka Pharma Co Ltd Thiazole derivatives, their production and use
DK1749836T3 (da) 1996-08-23 2009-08-31 Vegenics Ltd Rekombinant vaskulær endothelcellevækstfaktor D
US6093742A (en) * 1997-06-27 2000-07-25 Vertex Pharmaceuticals, Inc. Inhibitors of p38
JPH11130761A (ja) 1997-10-24 1999-05-18 Otsuka Pharmaceut Co Ltd ベンゾチアゾール誘導体
KR20010031912A (ko) * 1997-11-10 2001-04-16 스티븐 비. 데이비스 벤조티아졸 단백질 티로신 키나제 억제제
JPH11222431A (ja) 1998-01-30 1999-08-17 Otsuka Pharmaceut Co Ltd 医薬組成物
ES2251395T3 (es) 1999-07-26 2006-05-01 Banyu Pharmaceutical Co., Ltd. Derivados de biarilureas.

Also Published As

Publication number Publication date
IL151045A0 (en) 2003-04-10
SK12712002A3 (sk) 2003-02-04
CN1422262A (zh) 2003-06-04
WO2001057008A1 (en) 2001-08-09
NO20023713L (no) 2002-10-04
ZA200206235B (en) 2004-02-13
KR20020084116A (ko) 2002-11-04
CA2398754A1 (en) 2001-08-09
EP1254123A1 (en) 2002-11-06
BG107062A (bg) 2003-04-30
BR0108085A (pt) 2003-03-18
US7091227B2 (en) 2006-08-15
AU2001236698A1 (en) 2001-08-14
HUP0300359A2 (hu) 2003-06-28
JP2003521543A (ja) 2003-07-15
NO20023713D0 (no) 2002-08-06
PL357099A1 (en) 2004-07-12
AR030189A1 (es) 2003-08-13
US20030153568A1 (en) 2003-08-14

Similar Documents

Publication Publication Date Title
MXPA02007632A (es) Derivados de 2-benzotiazolil urea y su uso como inhibidores de proteina cinasa.
NZ517758A (en) Pyrazolopyrimidines useful as therapeutic agents
MXPA02005844A (es) Inhibidores de cinasas de proteina.
SG128491A1 (en) Heterocyclic sulfonamide inhibitors of beta amyloid production
ATE400274T1 (de) Hemmstoffe der akt aktivität
MY138352A (en) Benzothiazole derivatives
ATE512957T1 (de) Hemmer der akt aktivität
DE60237145D1 (de) Chinazolinderivate
ATE437872T1 (de) Proteinkinaseinhibitoren
MXPA03010961A (es) Compuestos de tiazol utiles como inhibidores de proteinas cinasas.
ATE503483T1 (de) Hemmer der akt aktivität
ATE446752T1 (de) Hemmer der akt aktivität
NZ508268A (en) Bicyclic pyrimidines and bicyclic 3,4- dihydropyrimidines as inhibitors of cellular proliferation
BG106585A (en) Kinase inhibitors as therapeutic agents
HK1065033A1 (en) Thiazole compounds useful as inhibitors or proteinkinases
NO20032801L (no) Tiazolderivater for behandling av PPAR-relaterte forstyrrelser
MY143400A (en) 2-pyridone derivatives as neutrophil elastase inhibitors and their use
RS50140B (sr) Postupak za dobijanje perkihinina i njegova upotreba
NO20051263L (no) Ny anvendelse av benzotiazolderivater
DK1240165T3 (da) N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamid-inhibitorer af cyclinafhængige kinaser
MXPA05011207A (es) Uso de derivados de 2,4-dihidro-[1,2,4]triazol-3-tiona como inhibidores de la enzima mieloperoxidasa (mpo).
ES2080900T3 (es) Derivados piranicos utiles como inhibidores de 5-lipoxigenasa.
MX2007013624A (es) Inhibidores de proteina cinasa.
MXPA04010055A (es) Derivados de tioxantina como inhibidores de mieloperoxidasa.
DE60002714D1 (de) Substituierte azaoxindolederivate